Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 7/20 | 0.72 |
| ▸ | CA1 | P00915 | 4/20 | 0.72 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.36 |
| ▸ | AKR1A1 | P14550 | 1/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | HTR2C | P28335 | 1/20 | 0.36 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.36 |
| ▸ | HRH1 | P35367 | 1/20 | 0.36 |
| ▸ | DRD3 | P35462 | 1/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 3/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.34 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.34 |
| ▸ | SLC1A2 | P43004 | 4/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4255669 | 0.86 | — | — | |
| SCHEMBL11677928 | 0.86 | CA2 (0.55) | CA2CA1MAPK1 | |
| SCHEMBL27970138 | 0.85 | CA2 (0.50) | CA2CA1MAPK1CHRM1AKR1A1 | |
| SCHEMBL11861708 | 0.84 | CA2 (0.53) | CA2CA1MAPK1 | |
| SCHEMBL7038841 | 0.84 | CA2 (1.00) | CA2CA1MAPK1SLC1A2SLC1A1 | |
| SCHEMBL376915 | 0.84 | CA2 (1.00) | CA2CA1MAPK1SLC1A2SLC1A1 | |
| SCHEMBL20145272 | 0.83 | — | — | |
| SCHEMBL18664252 | 0.83 | — | — | |
| SCHEMBL276427 | 0.83 | — | — | |
| SCHEMBL1537431 | 0.82 | CA2 (0.95) | CA2CA1MAPK1SLC1A2SLC1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3383865-A1 | FURANE DERIVATIVES AS INHIBITORS OF ATAD2 | Bayer Pharma Aktiengesellschaft (DE) | 2018-10-10 | — | — | EP | disclosed |
| WO-2017093272-A1 | FURANE DERIVATIVES AS INHIBITORS OF ATAD2 | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-06-08 | — | — | WO | disclosed |
| US-8093237-B2 | 11-(piperazin-1-yl)dibenzo[b,f][1,4]oxazapine compounds; psychological disorders, sleep disorders; antipsychotic agents that modulate monoaminergic neurotransmitter receptor subtypes; side effect reduction | ARYX THERAPEUTICS, INC. (US) | 2012-01-10 | — | — | US | disclosed |
| US-20080255088-A1 | DIBENZO[b,f][1,4]OXAZAPINE COMPOUNDS | PROTOCELL THERAPEUTICS INC. | 2008-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255088-A1 | DIBENZO[b,f][1,4]OXAZAPINE COMPOUNDS | DBH, DRD4, PSEN1 | CA2 4707/4885CA1 3287/4885MAPK1 2844/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.